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Forskolin, an activator of adenylate cyclase, and its analogs were studied on the nicotinic acetylcholine re- 
ceptor-ion channel complex (AChR) of rat and frog skeletal muscles. At nanomolar concentrations, forsko- 
lin caused desensitization of the AChR located at the junctional region of innervated and the extrajunctional 
region of chronically denervated rat soleus muscles. The desensitization of the AChR occurred without al- 
teration of the conducting state (channel lifetime, conductance or bursting) as shown by single channel cur- 
rents. Accordingly, forskolin decreased the peak amplitude of the repetitive voked endplate currents in frog 
sartorius muscles. These findings taken together with the good correlation found between the effects of fors- 
kolin and its analogs on the desensitization of the nicotinic AChR and their ability to activate adenylate 
cyclase suggested apossible involvement of phosphorylation of AChR via cyclic AMP on the desensitization 
process. 
Forskolin Nicotinic receptor cyclic AMP Desensitization Adenylate cyclase Acetylcholine sensitivity 
1. INTRODUCTION 
The release of acetylcholine (ACh) from the 
presynaptic nerve terminal of nicotinic synapses 
and subsequent binding to recognition sites located 
on the subunits of the ACh receptor-ion channel 
complex (AChR) results in conformational 
changes of the AChR which yield channel opening. 
The AChR, upon binding of the agonist, can also 
undergo a slow transition to a refractory or desen- 
sitized state [l-5]. This condition, brought about 
by very high concentrations of the agonist, may 
not be evident under physiological conditions since 
the quantity of ACh released during repetitive 
nerve firing does not appear likely to be sufficient 
to induce desensitization [6]. However, desen- 
sitization of the AChR may serve as an 
autoregulatory function, protecting the junctional 
region against excessive depolarization. A major 
question is whether mechanisms other than 
repetitive ACh binding to the AChR complex may 
participate in the desensitization process. 
An attractive possibility is phosphorylation of 
the AChR complex. Protein phosphorylation by 
specific protein kinases often has an 
autoregulatory role. Further, phosphorylation of 
the AChR complex has been demonstrated in elec- 
troplax membranes [7,8]. This phosphorylation 
appeared to involve a cyclic AMP (CAMP)- 
dependent protein kinase [9]. To investigate 
whether activation of CAMP-dependent protein 
kinases in situ could affect desensitization of the 
nicotinic AChR, the diterpene forskolin, a general 
activator of hormone-sensitive adenylate cyclases 
[lo,1 11, was investigated. Forskolin has been 
shown to activate fully CAMP-dependent control 
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of physiological processes in nerve and muscle at 
5 PM or less (for references see [ll]). Also, for- 
skolin has no effect on directly evoked contrac- 
tures of soleus muscle [12]. In this study forskolin 
was used in low concentrations (up to 5 PM) along 
with two close structural analogs, one of which, 
namely 14,l Sdihydroforskolin, is much less po- 
tent than forskolin in activating adenylate cyclase, 
while the other, 1 ,Pdideoxyforskolin, is inactive 
([13]; see fig.2 for chemical structures). The ac- 
tions of forskolin were investigated on the junc- 
tional region of innervated and extrajunctional 
region of the chronically denervated rat soleus 
muscles and on single channel currents in neonatal 
rat myoballs. We observed that at nanomolar con- 
centrations, forskolin induced receptor desen- 
sitization but had no effect on the properties of 
ACh-activated single channel currents, thus 
leading to the suggestion that this effect could 
result from a mechanism involving phosphoryla- 
tion of the AChR. 
2. MATERIALS AND METHODS 
2.1. Preparations and recording techniques 
In vitro preparations of innervated and 
chronically denervated soleus muscles from female 
Wistar rats (180-200 g) were used in these studies. 
Denervation of the muscles 10 days prior to the 
day of experiment and measurement of junctional 
and extrajunctional ACh sensitivity to microion- 
tophoretic application of ACh were performed ac- 
cording to [6,14,15]. Briefly, micropipettes filled 
with 3 M KC1 with a resistance of 15-25 MQ were 
used for recording ACh-induced potentials. The 
following procedure was observed for determina- 
tion of junctional ACh sensitivity: only muscle 
fibers having a membrane potential between - 70 
and - 80 mV were used. In a typical trial, the focal 
region of the endplate was located by the criterion 
of miniature endplate potentials (MEPPs) having a 
rise time of less than 0.8 ms. Once the focal region 
was found, without removing the recording 
microelectrode the tip of the ACh pipette was posi- 
tioned as close as possible to the AChR-rich junc- 
tional region and brief 0.2 ms charges were applied 
to the pipette yielding a potential whose rising 
phase was ~0.8 ms. In a typical trial of recording, 
the response to 1 or 2 single ACh-induced pulses 
was followed by a train of 100-200 pulses 
delivered at 8 Hz. At the end of the train, the 
response to single pulses was again determined. 
After 3-4 control steady responses the muscle was 
perfused with the drugs and the potentials record- 
ed every 10 min up to 60 min. The data shown here 
are from recordings made 30-60 min after drug 
perfusion. After this period, the preparation was 
washed for up to 60 min with the same solution 
F&l. Effect of forskolin (1 ,uM) on the junctional ACh sensitivity of the endplate region of innervated rat soleus 
muscle. Potentials generated by microiontophoretic application of ACh in a train of 100 pulses at 8 Hz were recorded 
from the same cell under control conditions (A), 30 min after perfusion of forskolin (B) and 30 min after wash (C). 
Membrane potential, - 70 mV. Vertical bar, ACh sensitivity (mV/nC). (Inset) The values of ACh sensitivity (mV/nC) 
shown in A (0), B (0) and C (A) are plotted vs time (s). Initial fast phase of desensitization lasting approx. 0.6 s (slope 
= -672 mV.nC-‘es-‘) was followed by a slow phase (slope = - 17.2 mV.nC-‘es-‘). 
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Fig.2. Effect of forskolin on the junctional sensitivity to 
microiontophoretic application of ACh at the endplate 
region of innervated rat soleus muscle. Each point, 
expressed in percent of the first response in a train of 200 
responses evoked at 8 Hz, represents the mean f SE of 
values recorded from at least 4 responses from 2 
muscles. The recordings were made from the same cell 
under control conditions (M), 40-60 min after 
either perfusion of 0.2 /tM (C--O) and 1 .O pM (U-U) 
forskolin or wash (s). (Inset) Chemical structures 
of forskolin (R = R’ = OH, R” = -CH = CH2); 
14,15dihydroforskolin (R = R’ = OH, R” = - 
CHzCH3); 1,9-dideoxyforskolin (R = R’ = H, R” = - 
CH = CHz). 
drug was added (0.5-1OOpM) was assayed ac- 
cording to a modification of the procedure by 
Ellman et al. [20]. The details of the procedure 
were as described [21]. 
2.3. Solutions and drugs 
The physiological solution had the following 
composition (in mM): 135 NaCI, 5 KCI, 2 CaC12, 
1 MgC12, 15 NaHCOj, 1 Na2HP04, 11 glucose; the 
pH was 7.2-7.3. ACh hydrochloride (Sigma) and 
tetrodotoxin (Calbiochem, TTX) solutions were 
freshly prepared from stock solutions stored at 
4°C. Forskolin (Calbiochem), 1 ,Pdideoxyfor- 
skolin and 14,Wdihydroforskolin were dissolved 
in absolute ethanol to 1 mM and stored at 4°C. 
Forskolin analogs were kindly provided by 
Hoechst Pharmaceutical Ltd (Bombay, India). 
TTX (0.1-0.3 ,uM) was added to the bathing 
medium to avoid spontaneous twitching of muscle 
fibers and cell movement during single channel 
recordings. 
used for control recordings. Throughout these ex- 
periments the rate of perfusion was kept optimum 
so as not to disturb the recording conditions. The 
volume of the muscle chamber was 20 ml and with 
the solution supplied to the chamber at a rate of 25 
drops/min a complete bath solution exchange was 
achieved in 9 min. The data presented for the junc- 
tional ACh sensitivity were obtained from the 
same fiber maintained throughout the control, 
drug-perfused, and recovery conditions. 
Patch-clamp studies employing the cell-attached 
configuration were performed on both myoballs 
cultured from neonatal rat skeletal muscles and 
muscle fibers isolated from interosseal and lum- 
bricalis muscles of adult frogs. The procedures for 
culture and isolation of the muscle fibers and the 
details of single channel current recordings were as 
described elsewhere [16- 181. The drug was applied 
as an admixture with ACh inside the patch pipette. 
Endplate currents (EPCs) were recorded from 
the frog sartorius nerve-muscle preparation ac- 
cording to [19]. 
2.2. Acetylchoiinesterase (AChE) assay 
AChE from soleus muscles exposed to 1 pM for- 
skolin and from muscle homogenates to which the 
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Fig.3. ACh potentials recorded at various concen- 
trations of forskolin on the extrajunctional region of 
denervated rat soleus muscles. Responses were evoked at 
8 Hz stimulation under control conditions (A) and 
30 min after perfusion of 0.1 (B), 0.5 (C) and 1 (D) PM 
forskolin. Complete recovery from desensitization was 
seen after 60 min wash (E). 
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3. RESULTS 
3.1. Effect of forskolin on ACh sensitivity of the 
junctional region of innervated soleus muscle 
To study the effects of forskolin on the response 
of the junctional region to microiontophoretically 
applied ACh the following approach was taken: 
determinations of high values for ACh sensitivity 
at the junctional region were obtained in the 
presence of physiological salt solution plus 
O.Ol-0.1% alcohol, since this was the vehicle for 
dissolving forskolin. The ACh sensitivity for the 
innervated junctional region varied from 1500 to 
5000 mV/nC. To avoid desensitization during con- 
trol conditions, the trains of 100-200 ACh poten- 
tials were evoked at frequencies of l-8 Hz. Fig.1 
shows experimental records of ACh sensitivity 
under control conditions, after 30 min exposure to 
forskolin (1 PM) and during washing depicting the 
recovery phase. After 30 min exposure to forskolin 
(0.2 and 1 PM) a significant depression of the 
amplitude of the ACh potentials was observed. 
While ACh potentials evoked at 1 Hz did not show 
any sign of desensitization, at 8 Hz a significant 
depression occurred such that at 1 gM forskolin by 
the 100th and 200th potentials the amplitudes of 
the ACh potentials had decreased by as much as 
60% of the initial value (fig.2). The depression was 
often characterized by a fast phase followed by a 
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Fig.4. Effect of forskolin on the extrajunctional ACh 
sensitivity of the chronically denervated rat soleus 
muscle. ACh potentials (100) evoked at 8 Hz were 
recorded under control conditions (o), 40-60 min after 
perfusion of 0.1 (o), 0.5 (m), 1.0 ( q ), or 5.0 (A) pM 
forskolin and 45-60 min after wash (A). Each point 
represents the mean f SE of values from at least 4-5 
fibers in 3 muscles, expressed as percent of the first 
Fig.5. Effect of 1,9-dideoxyforskolin and 14,15-di- 
hydroforskolin on the extrajunctional sensitivity to 
microiontophoretic application of ACh in the de- 
nervated soleus muscle of the rat. ACh potentials were 
evoked at 8 Hz under control conditions (0) and after 
perfusion with 1,9-dideoxyforskolin (0, 0.5 pM; q , 
l.OpM) or 14,15-dihydroforskolin (W , 0.4 pM; A , 
1.2 pM). Each point, expressed as percent of the first 
potential in a train of 100 potentials, represents the 
mean * SE of values obtained after 45-60 min drug 
potential in a train. perfusion from at least 3 fibers in 2 muscles. 
slow steady decay (fig. 1, inset). Upon cessation of 
the train, the amplitude of the ACh potentials 
returned to values identical to those generated at 
1 Hz (see fig.lB). The desensitization induced by 
forskolin was reversible upon washing the muscles 
for 30 to 60 min (see figs 1 and 2). 
3.2. Effect of forskolin and its analogs on the 
ACh sensitivity of chronically denervated rat 
soleus muscles 
Similar results to that observed on the junctional 
region of the innervated muscles were obtained on 
the chronically denervated soleus muscle in the 
presence of various concentrations (0.1-5 PM) of 
forskolin (figs 3 and 4). Under control conditions, 
no desensitization was observed (fig.3A); however, 
at concentrations as low as 0.1 PM, forskolin pro- 
duced depression of responses in a train which 
usually revealed one phase. ACh potential 
amplitude was fully recovered upon cessation of 
repetitive stimulation (fig.3). In addition, as seen 
with innervated muscles, no desensitization was 
observed after washing muscles with drug-free 
solution (fig.3E). 
To investigate whether the effects of forskolin 
were correlated with its known stimulatory effects 
on adenylate cyclase, two close structural analogs 
were tested. 1,9-Dideoxyforskolin, which is inac- 
tive with respect o activation of adenylate cyclase 
3 120 r-1 I I I I ’ 1 
I 1 I I 
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[IO], did not produce any effect on the ACh sen- 
sitivity at a concentration up to 1 pM (fig.5). 
14,15-Dihydroforskolin, which is about 8-fold less 
potent than forskolin as an adenylate cyclase ac- 
tivator [lo], at 0.4 and 1.2 /IM induced much less 
desensitization compared to forskolin. As shown 
in fig.5, 1.2 pM dihydroforskolin caused only 25% 
depression of the 100th ACh potential,. thus re- 
flecting a much weaker activity than the parent 
compound forskolin. The latter depressed the ACh 
potential by nearly 40% even at the concentration 
of 0.1 FM (see figs 3 and 4). Similar to forskolin, 
the effect of 14,15-dihydroforskolin was complete- 
ly reversible upon washing. 
3.3. Effect of forskolin on the ACh-activated 
single channel currents 
Single channel currents were recorded from 
cultured rat myoballs (6-day-old culture) under 
cell-attached patch configuration using a 
micropipette filled with either ACh (0.1 PM) alone 
or together with O.l-l.OpM forskolin. ACh, as 
has been reported [ 18,221, activated predominantly 
channel openings with conductance of 30 pS at 
20°C. The excessive number of fast events con- 
tributed to a departure from the single-exponential 
distribution. The best fit to a double-exponential 
function obtained by nonlinear regression provid- 
ed 7 values of 0.7 and 17.8 ms for the fast and slow 
phases, respectively. Addition of forskolin to the 
patch pipette solution did not cause significant 
change in either channel conductance, duration or 
distribution of the open times or in the frequency 
of channel openings. The bursting-type activity 
similar to that reported for high agonist concentra- 
tion [23] or for open channel blockers [25] was not 
observed. The effects of high concentrations of 
forskolin (up to 1OOpM) were also tested on the 
isolated frog muscle fibers. As in the rat myoballs, 
no significant changes in channel lifetime or con- 
ductance were observed. 
3.4. Effect of forskolin on endplate currents of 
frog sartorius muscles 
Preliminary EPC experiments on the 
neuromuscular junction of the frog sartorius 
muscles showed that only high concentrations 
(I-1OOpM) of forskolin decreased the EPC peak 
Fig.6. Samples of single channel currents recorded from rat myoballs. The recordings were performed under the cell- 
attached patch configuration with a micropipette filled with ACh either alone or in the presence of forskolin. 
Temperature, 20°C; holding potential, - 180 mV. 
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amplitude, but they had little or no effect on the 
decay time constant. Forskolin (100,uM) did not 
produce a marked departure from linearity of the 
current-voltage relationship of the EPCs. In addi- 
tion, the influence of the frequency of nerve 
stimulation on EPC amplitude was analyzed. 
Under control conditions, trains of EPCs evoked 
up to 50 Hz did not show any depression of the 
peak amplitude. However, in the presence of for- 
skolin (40-100 PM), trains of EPCs evoked at 
membrane potentials varying from -50 to 
- 150 mV at 50 Hz disclosed a significant depres- 
sion. The latter reached an apparent steady state 
by the 40th to 50th EPC (not shown). 
4. DISCUSSION 
Forskolin was used at concentrations at which it 
is effective in altering physiological responses 
mediated through CAMP in a variety of systems 
[ 111. Physiological responses are usually fully 
altered by concentrations of forskolin less than 
10 PM and in many cases with smooth muscle, car- 
diac preparations, or epithelial cells, the effects of 
forskolin on relaxation, contraction or ion 
transport occur with EDso of 200 nM or less. Con- 
centrations > 5- 10 PM were avoided since other 
‘nonspecific’ effects of forskolin, viz. direct in- 
teractions with AChR through allosteric or non- 
competitive mechanisms, may occur at such high 
concentrations as described for a variety of drugs 
151. 
This study demonstrated that forskolin, an ac- The sequence of receptor desensitization by for- 
tivator of adenylate cyclase, induces a reversible skolin appears to involve an initial fast phase 
AChR desensitization at the junctional and extra- followed by a slow almost steady-state second 
junctional regions of rat soleus muscles. Such an phase (see fig. 1). However, further quantitative 
action occurred without changing the kinetics of analysis is now in progress to clarify such an obser- 
open ion channels associated with the AChR such vation. A good correlation between the elec- 
that neither single channel conductance nor 
lifetime was affected. 
A 
350 
1 
10 20 30 40 
CHANNEL OPEN TIME (msec) 
B 
Fig.7. Open time histograms of the channels activated by ACh (0.1 PM) either alone (left) or together with forskolin 
(1 ,uM) from rat myoballs. 7 values for the fast (7t) and slow (TV) phases obtained from the best fit of the distribution 
to a double-exponential function (nonlinear regression) were: left: 7t = 0.7 ms, 7s = 17.8 ms; right: 7r = 0.5 ms, 7s = 
17.8 ms. (Inset) Histograms of the slow phase on an expanded scale. 
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trophysiological effect described here and the abili- 
ty of forskolin and some of its analogs to activate 
adenylate cyclase was observed. 1,9-Dideoxyfor- 
skolin, an analog that is inactive on adenylate 
cyclase [ 131, was unable to induce any sign of 
desensitization even at high concentrations. In ad- 
dition, compared to forskolin, 14,15dihydrofor- 
skolin, a less potent activator of adenylate cyclase 
[ 131, was less potent in inducing desensitization. 
Such structure-activity correlations strongly sug- 
gested a possible involvement of CAMP in the 
process of desensitization by forskolin. However, 
alternative mechanisms for induction of desen- 
sitization by forskolin can be considered. First, a 
blockade of AChR in the open state. This possibili- 
ty appears unlikely since no alterations in either 
channel lifetime or conductance were observed. 
However, a recent study [26] on effects of for- 
skolin (lo-30 PM) on synaptic transmission in 
sympathetic ganglia showed a decrease in the 
nicotinic receptor activity, which was postulated as 
perhaps due to a blockade of the open channel. 
Such a hypothesis was not confirmed here, Even at 
concentrations from 40 to 100/M forskolin, as 
revealed both directly by single channel recording 
and indirectly by the analysis of the decay time 
constant of the EPC, did not have any effects 
typical of open channel blockade [5,25]. Both 
presynaptic facilitation and ‘anticholinergic’ 
postsynaptic effects were reported in the study 
with sympathetic ganglia [26], and from our study 
it appears likely that the latter effects are related to 
the facilitatory effects of forskolin in desensitiza- 
tion. Second, forskolin might enhance desensitiza- 
tion through mechanisms that do not involve ac- 
tivation, bursting and marked decrease in frequen- 
cy of ion channel opening of the AChR as ob- 
served with noncompetitive blockers such as 
meproadifen [27,28] or high concentrations of 
agonist [23,24]. Bursting and decrease in frequency 
were not observed at any concentrations of for- 
skolin tested, 0.1-l PM in myoballs and 0.1-100 
PM in isolated frog muscle fibers. Although we 
have not observed a decrease in channel opening 
frequency, one possible explanation is that it has 
been missed due to the limitations inherent in the 
cell-attached patch technique and the variation in 
density of AChRs in the myoballs. It is also con- 
ceivable that a short bath incubation of the 
myoballs with forskolin prevents the accumulation 
of CAMP to a level which would phosphorylate the 
AChR leading to the appearance of signs char- 
acteristic of desensitization. Third, since forskolin 
(I-100 PM) did not induce voltage- and time- 
dependent effects on the EPCs as seen with many 
other noncompetitive antagonists of the AChR 
such as phencyclidine, phenothiazines, mepro- 
adifen and histrionicotoxin [5,6,27-291, the 
possibility of a blockade of AChR in the resting 
state seems unlikely. The possibility that the desen- 
sitization observed with forskolin could be due to 
continuous and excessive xposure to ACh because 
of a blockade of AChE by forskolin was also con- 
sidered. However, concentrations of l-1OOpM of 
the drug did not block AChE assayed in 
homogenates of soleus muscle. Under the present 
circumstances, taken together, the evidence sug- 
gests that he desensitization observed with for- 
skolin may be mediated via a mechanism involving 
an activation of adenylate cyclase by forskolin, 
resulting in CAMP formation, activation of 
CAMP-dependent protein kinase and phosphoryla- 
tion of the AChR. Phosphorylation of the AChR 
could occur either in the resting state or in states 
with bound ACh. Such phosphorylation would 
then enhance pathways leading to possible desen- 
sitized, nonconducting states. 
In conclusion it is suggested that forskolin, a 
general activator of hormone-sensitive adenylate 
cyclase, enhances desensitization via a process in 
which one or more of the subunits comprising the 
AChR macromolecule is phosphorylated by a 
CAMP-dependent protein kinase. 
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